 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Microcide Pharmaceuticals, Inc.
 |
Microcide Pharmaceuticals, Inc. |
 |
 |
 |
PROFILE |
 |
Microcide Pharmaceuticals puts disease under the microscope. The firm is developing new antimicrobials to fight drug-resistant bacteria, viruses, and systemic fungal infections. Microcide divides its research into two areas: Targeted Antibiotics and Targeted Genomics. Products in development may treat bacterial and fungal infections, viral infections such as HIV, and animal health infections. Microcide has research agreements with Daiichi Pharmaceutical, Pfizer, Johnson & Johnson's Ortho-McNeil Pharmaceutical and R.W. Johnson Pharmaceutical Research Institute, and Iconix, of which it owns about 30%. The company is set to buy The Althexis Company to strengthen its drug discovery work.
COMPETITION |
 |
Bristol-Myers Squibb Company (BMY)
Cubist Pharmaceuticals, Inc. (CBST)
IntraBiotics Pharmaceuticals, Inc. (IBPI)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 5.90
1-Yr. Sales Growth: (37.2)%
Employees: 104
Revenue per employee: $56,730.77
KEY PEOPLE |
 |
James E. Rurka
CEO
Donald D. Huffman
CFO
CONTACT INFO |
 |
850 Maude Ave.
Mountain View, CA 94043
US
Phone: 650-428-1550
Fax: 650-428-3550
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |